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Abstract
Cardiogenic shock is the second most common cause of circulatory shock, occurs  secondary 
to myocardial infarction, which accounts for 80% of the cases, and remains one of the lead-
ing causes of death in patients with acute myocardial infarction. Cardiogenic shock carries 
a high morbidity and mortality despite recent advances in medical and mechanical thera-
pies. Cardiogenic shock also occurs in non-acute coronary syndrome conditions, such as 
Takotsubo cardiomyopathy, fulminant myocarditis, end stage heart failure, and others. 
In this chapter, we provide a brief review on the pathophysiology, diagnosis, and acute 
management of cardiogenic shock patients. We will focus more on the management of acute 
coronary syndrome related cardiogenic shock, given that it is the most common etiology.
Keywords: cardiogenic shock, acute coronary syndrome, hemodynamic support, mechan-
ical circulatory support devices, vasopressors, inotropes
1. Definition
Circulatory shock is defined as the failure to meet the body’s cellular oxygen demands. It 
typically occurs when the systolic blood pressure falls below 90 mmHg or the mean arterial 
blood pressure falls below 65 mmHg for 30 min. In circulatory shock there are signs of tissue 
hypoperfusion such as altered mental status, decreased urine output (<0.5 ml/kg/h), cold and 
clammy skin, and elevated serum lactic acid level (>1.5 mmol/l) [1].
Cardiogenic shock (CS) is the shock that results from cardiac causes and can be defined as 
a circulatory failure in addition to severely reduced cardiac index (<1.8 L/min/m2 without 
support or <2.0–2.2 L/min/m with support) in the presence of adequate filling pressures 
(left  ventricular end diastolic pressure (LVEDP) > 18 mmHg or right ventricular end diastolic 
 pressure >10–15 mmHg) [2].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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To differentiate CS from other types of shock, the following general hemodynamic measures 
can be used with the help of echocardiography or pulmonary artery catheterization (Table 1).
2. Epidemiology
CS is the second most common type of circulatory shock representing 16% of patients 
 presenting with shock [3]. CS complicates up to 8.6% of patients with ST segment  elevation 
myocardial infarction (STEMI) and about 2.5% of patients with non-ST segment  elevation myo-
cardial infarction (NSTEMI), and remains one of the leading causes of death in patients 
 presenting with acute myocardial infarction (AMI) [4]. Despite the advancement in the 
 medical and technological management, CS carries a poor prognosis with high  morbidity 
and mortality (40–60% of patients with CS will die within 6 months) [5–7].
AMI is the most common cause of CS, and patients with AMI older than 75 years tend to pres-
ent more frequently with CS than patients younger than 75 [2–4, 8].
3. Etiology and pathophysiology
Acute coronary syndrome (ACS) leading to ischemia and left ventricular (or right ventricu-
lar) failure is the leading cause of CS and represents around 80% of CS cases (8% of those 
are caused by mechanical complications of AMI such as ventricular septal rupture, free wall 
rupture, papillary muscle rupture and acute mitral regurgitations) [7].
The pathophysiology of ischemia leading to CS is illustrated as a vicious cycle in Figure 1. AMI 
may lead to severe left ventricular (LV) dysfunction and pump failure. The hypotension that 
accompanies CS leads to the release of inflammatory cytokines and catecholamines leading 
to increased contractility, which in turn leads to increased myocardial oxygen demand that 
Cardiogenic Distributive (e.g. 
septic shock)
Hypovolemic Obstructive
PE Tamponade
PCWP/LVEDP
Unchanged or 
Usually 
unchanged
SVR
or unchanged
CI/CO
 But might be 
PCWP, pulmonary capillary wedge pressure, LVEDP, left ventricular end diastolic pressure; SVR, systematic vascular 
resistance; CI, cardiac index; CO, cardiac output.
Table 1. General hemodynamic measures to differentiate between cardiogenic shock and other types of shock.
Interventional Cardiology142
causes worsening of the ischemia and shock state. The increase in catecholamines also causes 
peripheral vasoconstriction that in turn leads to an increase in the afterload, worsening the 
ischemia and the shock state [2].
CS also occurs in the absence of coronary artery disease; those etiologies represent around 
20% of CS cases. The non-ACS-related CS patients tend to do slightly better than those with 
ACS [7]. Those conditions may include hypertrophic cardiomyopathy, end stage heart fail-
ure, acute fulminant myocarditis, severe valvular stenosis, and acute valvular regurgitation 
secondary to trauma or infection. CS complicates about 10% of patients presenting with 
Takotsubo cardiomyopathy and carries a poorer prognosis than the rest of Takotsubo cardio-
myopathy population [1, 9, 10].
CS could also occur secondary to right ventricular (RV) dysfunction and failure second-
ary to RV ischemia, acute pulmonary embolism, pulmonary hypertension (PH) and others 
[2, 11, 12].
The right ventricle is affected in nearly 50% of inferior STEMI patients, however, RV infarction 
leading to CS occurs in approximately 5% of CS cases caused by AMI; despite that, it carries 
high mortality similar to that of LV failure. RV failure leads to decreased transpulmonary 
delivery of LV preload and intraventricular dependence, which in turn may lead to decreased 
LV filling. The RV end diastolic pressure in CS secondary to RV failure is usually very high, 
exceeding 20 mmHg [2, 11–13].
Figure 2 summarizes the most common causes of CS.
Figure 1. The vicious cycle of cardiogenic shock. SV, stroke volume; CO, cardiac output; LVEDP, left ventricular end 
diastolic pressure; MCS, mechanical circulatory support.
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4. Diagnosis and clinical presentation
The diagnosis of CS requires a high index of suspicion due to its high morbidity and mortal-
ity. It should be noted that up to 70% of patients with CS will develop shock later during their 
hospital stay [4].
Most patients with CS are critically ill and might complain of chest pain and/or dyspnea. 
There are physical exam findings that are more specific to CS than other types of shock, such 
as elevated jugular venous pressure (JVP), S3 gallop and the presence of pulmonary rales. In 
fact, the presence of elevated JVP > 8 cmH
2
O and rales more than one-third of the lung bases 
predicted CS with very high sensitivity and specificity [14]. The risk factors that are associated 
with a higher risk of CS in ACS patients are female gender, diabetes mellitus, anterior wall MI, 
prior history of MI and older age [14, 15].
Other signs and symptoms of CS are generally those of tissue hypoperfusion, such as the 
presence of hypotension (SBP < 90 mmHg or MAP < 65 mmHg) in addition to tachycardia, 
altered mentation, decreased urine output and cold and clammy skin.
Electrocardiogram (ECG) and chest X-ray (CXR) should be obtained in all patients presenting 
with shock. CXR in CS may show pulmonary edema, pleural effusion, pulmonary vascular 
congestion or enlarged cardiac silhouette. Cardiac troponin is also mandatory for all patients 
with suspicion of shock from cardiac causes at the time of presentation and then repeated 
within 3–6 h [16].
ECG can help diagnose acute STEMI, Q waves or any active cardiac ischemia; although in a 
routine general practice only about 50% of patients with suspected NSTEMI will have ECG 
changes that are diagnostic of myocardial infarction at the time of presentation [17].
Figure 2. The most common causes of cardiogenic shock. (A) ACS represents 80% of CS cases, (B) non-ACS etiologies, 
which represent 20% of CS causes. ACS, acute coronary syndrome; LV, left ventricle; RV, right ventricle; HCM, 
hypertrophic cardiomyopathy; ADHF, acute decompensated heart failure; CMP, cardiomyopathy; PE, pulmonary 
embolism; PAH, pulmonary arterial hypertension.
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The presentation ECG carries prognostic information, as well, and can identify high-risk 
patients. In an analysis from the SHOCK trial [17], which included CS patients caused by 
AMI, a higher baseline heart rate was associated with a higher one-year mortality. Also, in CS 
patients secondary to inferior MI who received medical management, a longer QRS duration 
and a higher sum of ST segment depression in all leads were associated with a higher one-
year mortality [17].
Echocardiography is of utmost importance in the evaluation of shock patients especially 
when the etiology of shock is not well established. It is noninvasive and readily available at 
bedside. It helps identify severe valvular regurgitant or stenotic lesions, evaluate for ventricu-
lar or septal rupture post-AMI and check for cardiac tamponade.
Two-dimensional echocardiography allows for the identification of LV ejection fraction, 
assessment of segmental wall motion abnormalities and RV function. Doppler echocardiogra-
phy allows for the assessment of early mitral filling velocity (E) and the mitral annulus tissue 
velocity (e’) which greatly helps the clinician identifying elevated LV filling pressures with 
excellent sensitivity and specificity. E:e’ > 15 correlates with LVEDP > 14 mmHg and E/e’ < 8 
correlates with normal LVEDP [18, 19].
Pulmonary artery (PA) catheterization—Swan-Ganz catheter—is an excellent tool for confirm-
ing the diagnosis and guiding the medical and mechanical management. In CS, there is an 
increase in the right atrial (RA) pressure, RV systolic and diastolic pressures and pulmonary 
capillary wedge pressure (PCWP), and a decrease in the cardiac output and index (Figure 3). 
SVR can also be calculated using the PA catheter and is frequently elevated in CS patients. 
Currently, the main indication for PA catheter use is to establish the diagnosis of CS when the 
Figure 3. The pressure volume loop in cardiogenic shock. The left loop is that of a normal individual while the right one 
is the CS loop. In CS, there is an increase in LVEDP and LVDEV; there is a decrease in contractility and SV. LVEDP, left 
ventricular end diastolic pressure; LVESP, left ventricular end systolic pressure; LVEDV, left ventricular end diastolic 
volume; SV, stroke volume; AVO, aortic valve opens; AVC, aortic valve closes; MVO, mitral valve opens; MVC, mitral 
valve closes; IVC, isovolumetric contraction; IVR, isovolumetric relaxation.
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clinical picture is not clear, or when hemodynamic stabilization is not achieved despite esca-
lating doses of vasopressors and inotropes. PA catheter is also recommended when mechani-
cal circulatory support devices are considered. It should be noted that the routine use of PA 
catheter is discouraged in patients with a confirmed diagnosis and those who stabilize rather 
quickly [20].
5. Treatment
Since the most common etiology behind CS is ACS, the mainstay of therapy is coronary 
revascularization to relieve the vicious cycle of ischemia-shock state. Treatment also involves 
general supportive measures, pharmacotherapy, vasopressors, inotropes and mechanical 
 circulatory support (MCS) in the setting of refractory shock (Figure 4).
5.1. General measures and pharmacotherapy used in acute coronary syndrome
All patients with suspected AMI—STEMI or NSTEMI—should receive a loading dose of aspi-
rin (162–325 mg) as a chew non-enteric coated capsule and a maintenance dose of aspirin 
should be continued indefinitely after that. A high dose statin (atorvastatin 80 mg) is also 
indicated in all patients presenting with AMI without contraindications and should be contin-
ued indefinitely. Treatment with high dose statins for ACS patients reduced the risk of death, 
recurrent myocardial infarction, stroke and the need for coronary revascularization. Oxygen 
therapy is indicated for all patients with hypoxemia (O
2
 saturation < 90%) [16, 21].
Figure 4. Cardiogenic shock treatment flow chart. CXR , chest X-ray; PA, pulmonary artery; EMBx, endomyocardial 
biopsy; A.C.S, acute coronary syndrome; BB, beta blockers; ACE-I, angiotensin converting enzyme inhibitors; ARB, 
angiotensin receptor blockers; LVAD, left ventricular assist device; Bi-VAD, biventricular assist device; CHF, congestive 
heart failure; GCM, giant cell myocarditis; TPA , tissue plasminogen activator; PE, pulmonary embolism; PH, pulmonary 
hypertension; PAH, pulmonary artery hypertension; BAV, balloon aortic valvuloplasty.
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Beta blockers (BB), angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor 
blockers (ARB) should be avoided in patients at risk for CS [16, 21].
In patients with STEMI, a loading dose of a P2Y12 inhibitor should be administered as early as 
possible or at the time of primary coronary intervention (PCI) (clopidogrel 600 mg, ticagrelor 
180 mg or prasugrel 60 mg). Patients with NSTEMI who are undergoing early revasculariza-
tion should also receive a loading dose of a P2Y12 inhibitor as soon as possible. It should be 
noted that prasugrel is contraindicated in patients with prior history of stroke or transient 
ischemic attack (TIA) [16, 21–23].
All patients with STEMI undergoing PCI should receive anticoagulation unless they have 
contra-indications. Unfractionated heparin (UFH) can be used with or without glycoprotein 
(GP) IIb/IIIA inhibitors. The recommended dose of UFH is 50–70 units/kg as IV bolus if used 
with GP IIb/IIIa inhibitors to achieve a therapeutic activated clotting time (ACT) of 200–250 s, 
or 70–100 u/kg as a bolus if used without GP IIb/IIIa inhibitors to achieve therapeutic ACT of 
(250–300 s). Bivalirudin can be used in STEMI patients as well, and is preferred as a monother-
apy over the combination of UFH-GP IIb/IIIa inhibitor in patients at high risk for bleeding [21].
In patients with NSTEMI the anticoagulation regimen differs slightly from patients with 
STEMI, UFH can be used with a loading dose of 60 u/kg (maximum dose of 4000 units) fol-
lowed by infusion of 12 u/kg/h with (maximum dose of 1000 u/h) adjusted to keep therapeutic 
activated partial thromboplastin time (PTT) during the period of treatment. Enoxaparin is 
another option for anticoagulation at a dose of 1 mg/kg every 12 h. Most NSTEMI patients 
presenting with CS will undergo early revascularization, which makes bivalirudin another 
good option for anticoagulation as bivalirudin is only indicated in NSTEMI patients who 
undergo early invasive strategy [16].
Most clinicians prefer to use UFH in the setting of CS complicating an NSTEMI given that 
most of these patients will undergo early invasive strategy, and UFH has the advantage to 
turn on and off, or even reverse rather easily.
GP IIb/IIIa inhibitors might be considered for NSTEMI patients undergoing early invasive 
strategy and are treated with dual antiplatelet therapy (DAPT) [16].
5.2. Revascularization
Early revascularization is the cornerstone of treatment in AMI patients presenting with CS. 
The randomized SHOCK trial proved a statistically significant mortality benefit at 6 months 
in AMI patients complicated by CS treated with emergency revascularization as opposed 
to medical stabilization [5]. The non-randomized SHOCK registry also showed the same 
 mortality benefit of early revascularization in patients older than 75 [24].
The goal in STEMI patients is first medical contact (FMC) to device time of less than 90 min, 
and revascularization can still be done even up to 12 h after ischemic symptoms onset. But, in 
patients with CS complicating a STEMI, revascularization should be performed regardless of 
the time of symptoms onset. It is also reasonable to intervene on non-infarct arteries in STEMI 
patients complicated by CS at the time of PCI [21].
Cardiogenic Shock
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Early revascularization within 2 h of presentation should be done in all NSTEMI patients 
with CS, as well as those with high-risk features (such as refractory angina, electrical instabil-
ity, signs of heart failure or worsening mitral regurgitation, as well as sustained ventricular 
tachycardia or fibrillation) [16].
PCI is not the only option for revascularization; coronary artery bypass grafting (CABG) 
should be considered especially if successful PCI is not feasible, there are mechanical com-
plications such as ventricular septal or papillary muscle rupture, and in those with left main 
disease or three vessels, CAD. Emergent CABG can be done within 2–4 h in capable facilities 
[16, 25].
Thirty-six percent of patients undergoing revascularization in the SHOCK trial underwent 
CABG; those patients were more likely to be diabetic and have left main or three vessels CAD. 
The survival rate at 30 days and at 1 year was similar between those who underwent PCI or 
CABG in the SHOCK trial [26].
Compared to patients without CS undergoing CABG, those with CS were more likely to have 
had suffered AMI within 24 h prior to CABG, were more likely to have left main disease, have 
lower ejection fraction and were more likely to have intra-aortic balloon pump (IABP) used 
preoperatively [25].
It should be noted that patients with CS undergoing CABG have worse morbidity and mortal-
ity and longer intensive care unit (ICU) stay than those without CS. And even though older 
age was associated with higher morbidity and mortality, around 70% of patients with CS 
above the age of 75 survived this major surgery making CABG suitable for carefully selected 
elderly CS patients [25].
5.3. Fibrinolysis
If PCI cannot be performed within 120 min of FMC in STEMI patients, fibrinolytics can be 
used in those without contraindications and even up to 12 h after symptoms onset, and up 
to 24 h in those with large areas of ischemia, hemodynamic instability, or have clinical or 
ECG signs of continuous ischemia. Table 2 summarizes the absolute contraindications to 
fibrinolysis [21].
Any prior intracranial hemorrhage Any active bleeding or bleeding diathesis (not including 
menses)
Known malignant intracranial neoplasm Suspected aortic dissection
Known cerebral structural vascular lesion Ischemic stroke within the past 3 months (except for 
those with ischemic stroke in the past 4.5 h)
Severe uncontrolled refractory hypertension Any significant closed head or facial trauma in the past 
3 months
Intracranial or intraspinal surgery in the past 2 months If streptokinase is used, prior treatment within the 
previous 6 months (streptokinase is antigenic)
Table 2. Absolute contraindications to fibrinolytics [21].
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Patients with RV infarction secondary to proximal right coronary artery (RCA) occlusion with 
extensive clot burden might be resistant to fibrinolytic therapy; there is also a higher rate of 
re-occlusion after thrombolysis of the RCA [13, 27, 28].
Patients with CS secondary to STEMI who are treated with fibrinolytics should be transferred 
immediately to a PCI-capable facility after receiving fibrinolysis.
In patients with NSTEMI, fibrinolytics are contraindicated; those patients should be stabilized 
and transferred immediately to a PCI-capable facility for coronary angiography and revascu-
larization [16].
5.4. Vasopressors and inotropes
There is no optimal vasopressor or inotrope in the setting of CS, but catecholamines are 
the most frequently used vasopressors, with norepinephrine and dopamine being the most 
widely used. Catecholamines exhibit their effects through the stimulation of A1, B1, B2, and 
dopaminergic receptors (D1 and D2) [9, 29].
Norepinephrine is a potent A1 agonist; it induces an increase in systolic blood pressure (SBP), 
diastolic blood pressure (DBP), and the pulse pressure. Norepinephrine has minimal effect on 
myocardial contractility and HR [29].
Dopamine produces a multitude of effects at different doses: at lower doses (<3 ug/kg/min), 
it works primarily on the D1 receptors and causes coronary and renal vasodilatation; at inter-
mediate doses (3–10 ug/kg/min), dopamine stimulates the B receptors and causes an increase 
in inotropy and HR; and at higher doses (10–20 ug/kg/min), dopamine works primarily on A1 
receptors and causes vasoconstriction. The renal vasodilatory effect—so-called renal dose—
of low dose dopamine remains controversial, and glomerular filtration rate (GFR) does not 
change with use of those renal doses of dopamine [30, 31].
Epinephrine has high affinity towards A1, B1 and B2 receptors, with B effects more pro-
nounced at lower doses and Alpha effects at higher doses. Prolonged use of epinephrine is 
associated with direct cardiac toxicity through damage to the arterial wall that results in myo-
cardial necrosis and stimulation of myocyte apoptosis [29, 32].
Vasopressin or “antidiuretic hormone” is a non-adrenergic vasopressor; it stimulates the 
V1 and V2 receptors. The stimulation of the V1 receptors causes vasoconstriction while the 
stimulation of the V2 receptors enhances water reabsorption in the renal collecting ducts. 
It augments the pressor effect of norepinephrine and has no effect on cardiac output (CO). 
Vasopressin’s pressor effect is relatively preserved during the acidotic state that develops in 
most shock patients [29, 33].
Dobutamine is a B1 and B2 agonist; it primarily induces an inotropic effect, exhibits a mod-
est increase in HR and causes peripheral vasodilatation through the stimulation of B2 recep-
tors. Dobutamine induces an increase in the cardiac output and a reduction in the LVEDP. 
Pharmacologic tolerance to dobutamine usually develops after 72 h of use. Dobutamine could 
induce arrhythmias, myocardial ischemia and tachycardia, especially at higher doses (>15 ug/kg/
min), but these effects are reversed rather rapidly due to the short half-life of the drug (2.3 min). 
Cardiogenic Shock
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The prolonged use of dobutamine (7–52 days) is associated with much higher 6-month mortality 
[29, 30, 34–36].
Milrinone is a noncatecholamine inotrope and peripheral vasodilator, has lusitropic effect 
and has less effect on HR than dobutamine. Milrinone works through the inhibition of phos-
phodiesterase enzymes (PDE), which in turn, leads to an increase in intracellular cyclic ade-
nosine monophosphate (cAMP), which leads to an increase in the rate of entry and removal 
of calcium from the cardiac myocytes thus increasing myocardial contractility. Milrinone has 
been mainly used in the treatment of advanced severe heart failure patients, and—to date—
there have been head-to-head trials comparing dobutamine to milrinone. Milrinone should be 
avoided in advanced kidney disease patients as it is cleared renally [30, 37, 38].
Levosimendan is a calcium-sensitizing agent that enhances myocardial inotropy and lus-
itropy and causes peripheral vasodilation, and it is not yet approved for use in the USA. 
Levosimendan is associated with similar mortality rates as compared to dobutamine but it 
tends to cause more peripheral vasodilation and hypotension than dobutamine [30, 39, 40].
Norepinephrine is preferred over dopamine as dopamine has been associated with a higher 
incidence of arrhythmias and a higher rate of death at 28 days in the CS patient subgroup [3].
In CS secondary to RV infarction, IV fluids are always the first line, but the excessive admin-
istration of IV fluids beyond an RA pressure of 15 mmHg could result in the deterioration 
of LV performance, and the use of dobutamine in this scenario can be particularly help-
ful in improving myocardial performance. Despite the severe hemodynamic compromise, 
arrhythmias, and increased in-hospital mortality, many patients with severe RV infarction 
recover within 3–10 days and typically, global RV function recovers within 3–12 months 
[13, 29, 41].
Vasopressors and inotropes are essential in stabilizing CS patients but caution should always 
be taken with their use. The use of these agents causes an increase in the myocardial oxygen 
demand and can induce arrhythmias, and thus their use should always be individualized 
and guided by hemodynamic monitoring. The long-term use of inotropes is strongly discour-
aged, and should only be considered as a bridge to heart transplantation or ventricular assist 
devices (VAD) or as a palliative therapy in advanced heart failure patients [20, 29].
It is recommended to combine two small doses of vasopressors and inotropes than the use 
of a maximal dose of a single agent to avoid dose-related adverse events, also, the addition 
of vasopressin can help with “catecholamine sparing” [29]. The use of epinephrine in CS 
patients is associated with higher 90-day mortality independent of a prior cardiac arrest, and, 
thus, its use is discouraged unless it is a last resort medication [42].
Our experience with these vasoactive agents in CS has been to initiate norepinephrine fol-
lowed by an inotrope and then a stepwise approach in the addition of further vasopressors 
and/or inotropes in the setting of refractory shock. A concomitant shock etiology, such as 
septic shock, should always be investigated as the choice of these agents might differ.
References [20, 29] provide further information about inotropes and their mechanism of 
action.
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6. Mechanical circulatory support devices
In certain patients with CS, hemodynamic stabilization might not be achieved despite aggres-
sive pharmacotherapy and revascularization, as a result, percutaneous mechanical circulatory 
support (MCS) devices might be considered for temporary stabilization [43]. The optimal 
MCS device offers rapid hemodynamic stabilization along with a low complication rate. To 
date, no trial has shown mortality benefit with the use of these devices in CS patients.
6.1. Intra-aortic balloon pump counterpulsation
IABP counterpulsation is the most common form of percutaneous LV support. The original 
idea of counterpulsation started in the 1960s as an external counterpulsation device stimulat-
ing the hemidiaphragm around the distal thoracic aorta with each diastole. IABP is implanted 
percutaneously through either of the femoral arteries using a double lumen catheter that is 
7.5–8 Fr and is placed in the thoracic aorta with its tip distal to the left subclavian artery take 
off, and its proximal portion above the renal vessels (Figure 5) [43, 44].
IABP is a form of internal counterpulsation and acts as an assisting circulatory support device 
that inflates during diastole and deflates during systole. Its main mechanism is by diastolic 
augmentation during inflation that contributes to the coronary, cerebral, and systemic circu-
lation. The presystolic deflation lowers the impedance to systolic ejection and subsequently 
lowers the myocardial work and oxygen demand. IABP usually causes between 0.5 and 1.0 
Figure 5. Intra-aortic balloon pump. The left panel shows the balloon inflation during diastole and the right panel shows 
the balloon deflation during systole. Reproduced with permission from Getinge.
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L/min increase in the CO. IABP induces around 10% drop in SBP indicating proper systolic 
unloading, causes an increase in DBP which in turn improves the coronary perfusion and 
leads to a net increase in the mean arterial pressure (MAP). There is also an increase in the 
LV ejection fraction with IABP and a decrease in the LV end diastolic volume and pressure 
[44–47].
Despite all the hemodynamic advantages with IABP, studies have failed to show any mortal-
ity benefit with its use. The SHOCK II trial, which compared IABP vs. medical stabilization, 
showed no difference in mortality along with other variables such as time to hemodynamic 
stabilization, length of ICU stay, the dose and duration of catecholamines, and changes in 
renal function [6, 48].
Currently the main indication for IABP counterpulsation is CS refractory to pharmacother-
apy; IABP is currently a class IIa indication for the treatment of CS complicating a STEMI 
in the American Heart Association/American College of Cardiology guidelines (AHA/ACC), 
while its routine use in CS is discouraged by the European Society of Cardiology [21, 49].
Other indications where IABP can help stabilize the patient include refractory heart failure, 
papillary muscle rupture or acute mitral regurgitation, ventricular septal rupture, refrac-
tory unstable angina, high-risk PCI or the inability to wean from cardiopulmonary bypass 
[44, 49, 50].
The absolute contraindications to IABP are significant aortic regurgitation and aortic dissec-
tion. Other relative exclusion criteria include: significant peripheral arterial disease (PAD) that 
precludes placement, severe coagulopathy, active infection, and cancer with metastasis [44].
The complication rate with IABP is rather rare with thrombocytopenia and fever being the 
most common (about 50% and 40% of patients, respectively). Other major complications 
include: major limb ischemia (0.9% of patients); severe access site bleeding (0.8%); amputation 
(0.1%); balloon leak (1%); and IABP-related mortality (0.05%). The main risk factors associ-
ated with IABP complications are female gender, PAD, small body surface area (BSA) (BSA < 
1.65 m2), and advanced age (>75 years) [51, 52].
Due to the lack of data, the use of anticoagulation with IABP is variable among different 
centers. Most centers, like ours, use anticoagulation, but some will not, especially with 1:1 
pumping [43].
6.2. Impella devices
The Impella device is a nonpulsatile, axial flow device that is implanted inside the LV percu-
taneously, commonly through the femoral artery for the 2.5 Impella or with surgical cutdown, 
commonly through the axillary artery for the 5.0 Impella. The Impella acts as a pump that 
propels blood from the LV into the ascending aorta (Figure 6) [43].
The Impella device has three versions; 2.5 Impella, which is a 12 Fr system that provides a 
maximal flow of 2.5 L/min, the 5.0 Impella which is a 21 Fr system and provides a maximal 
flow of 5 L/min, and the CP Impella, which is a 14 Fr system that provides between 3 and 4 L/
min of flow [43, 53].
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The Impella unloads the LV, reduces the left ventricular end diastolic volume (LVEDV) and 
the LV wall tension and improves the systemic and coronary perfusion through an increase 
in the mean arterial pressure. The Impella device requires an adequate RV function (or an RV 
assist device) to maintain adequate LV preload, and unlike the IABP, the Impella devices can 
work properly through transient arrhythmias.
The main indications of the Impella devices are similar to those of the IABP counterpulsation 
with slight differences, for example, the Impella may worsen right-left shunting in patients 
with ventricular septal defect (VSD).
The main contraindications to Impella are mechanical aortic valve and LV thrombus. Other 
relative exclusion criteria are severe aortic regurgitation and severe PAD. The most com-
mon complications are those of vascular nature such as access site bleeding, retroperitoneal 
Figure 6. The Impella device with the pump inside the left ventricle and the outer catheter inside the aorta. Reproduced 
with permission from Abiomed.
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 hematoma, limb ischemia and vascular injury. Hemolysis is also common with the Impella 
device due to the mechanical shear stress of the device on the red blood cells. In addition, 
anticoagulation is generally required during treatment with Impella [43, 53].
Compared to the IABP, Impella does provide greater hemodynamic support but it has not 
been shown to change the mortality [54]. In the largest most recent randomized controlled 
trial (the IMPRESS trial) comparing Impella to IABP in CS complicating AMI; 48 patients 
with severe CS complicating STEMI were randomized to the Impella device (24 patients) and 
to IABP (24 patients), the mortality at 30 days and at 6 months was similar between the two 
groups (50% in both groups at 6 months). Of note: those were extremely ill patients with 92% 
of the entire group having cardiac arrest prior to randomization, and half the mortality at 6 
months was attributed to brain damage in both groups [55].
And although not commonly done, the successful use of Impella in combination with IABP 
has been reported [56].
A brief comparison between the Impella and the IABP is summarized in Table 3.
6.3. Other percutaneous mechanical circulatory support devices
The IABP and the Impella are not the only circulatory support devices used in CS, there are 
other—less commonly used—devices such as the Tandemheart, the extracorporeal membrane 
oxygenation (ECMO) and others.
The TandemHeart is left atrial to aorta support device that is inserted percutaneously and 
requires a transseptal puncture to access the left atrium. It bypasses the LV and pumps blood—
extracorporeally—from the left atrium into the iliofemoral arterial system (Figure 7) [43, 57].
Impella IABP
ECG Unrelated to systole or diastole Inflates with diastole and deflates 
with systole
CO Up to 5 L/min of CO Modest increase in CO (0.5–1 L 
increase CO)
LVEDV Reduces LVEDV and LVEDP Reduces LVEDV and LVEDP
Catheter size Between 12 and 21 Fr 7.5–8 Fr
Rhythm Does not require a stable rhythm (although 
asystole and VF are poorly tolerated)
Requires a stable rhythm
Absolute contraindications Mechanical AV, LV thrombus Severe AR, aortic dissection
Complications Similar complication profile of vascular injury and access site bleeding, with these 
complications being slightly higher with the Impella
Mortality No difference in mortality between both devices in CS patients complicating AMI
CO, cardiac output; LVEDV, left ventricular end diastolic volume; LV, left ventricle; AV, aortic valve; AR, aortic 
regurgitation.
Table 3. A brief comparison between intra-aortic balloon pump (IABP) and Impella.
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The TandemHeart device has two separate catheters, a 21 Fr venous catheter that goes 
 transseptally and aspirates the LA blood and an arterial perfusion outflow cannula between 
15 and 19 Fr. The TandemHeart pump can provide flow rates up to 4.5 L/min of assisted car-
diac output [8, 43].
The TandemHeart has been studied in severe refractory CS patients not responding to vaso-
pressors/inotropes in combination with IABP. The TandemHeart significantly improved the 
hemodynamics in this extremely ill population, along with PCWP, lactic acid levels and cre-
atinine levels. This device can also be used as a bridge to a more definitive therapy such as left 
ventricular assist device (LVAD) or heart transplantation [28].
ECMO can provide a full pulmonary and/or cardiac support for those with failing hearts 
and/or lungs. The ECMO device can be either venoarterial (V-A ECMO) or venovenous (V-V 
ECMO); the V-A ECMO is ideal for those with CS and poor oxygenation while the V-V ECMO 
provides oxygenation only when the cardiac hemodynamics are stable. The venous catheter 
size is usually 20 Fr and the arterial catheter size is 17 Fr. ECMO can provide even more than 
6 L/min of CO depending on catheter size and unlike other MCS devices, a trained perfusion-
ist is required to manage the ECMO [43].
Figure 7. The TandemHeart. The left panel shows the entire system: there is a venous catheter and an arterial catheter, 
and the pump is situated extracorporeally. The right panel shows the transseptal puncture and how the venous catheter 
bypasses the left ventricle. Reproduced with permission from Tandemlife.
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IABP, Impella, TandemHeart and ECMO can all be used in the setting of CS with slight 
differences in indications. They offer hemodynamic support, and it is recommended that 
one of these devices be inserted rapidly in CS if hemodynamic stability cannot be achieved 
with fluid resuscitation and/or pharmacotherapy. The experience with these devices in CS 
patients has been to start with an IABP along with vasopressors/inotropes, and if hemo-
dynamic stability cannot be achieved, one may consider upgrading to one of the more 
powerful percutaneous MCS devices. Although these devices are FDA approved for the 
use of up to 6 h, they have been used successfully for days in patients with prolonged 
shock [43].
Our center’s experience is to insert an IABP or an Impella—depending on operator’s expe-
rience—rapidly in CS patients secondary to AMI prior to attempted revascularization. We 
recommend—as it is endorsed by the 2015 SCAI/ACC/HFSA/STS consensus document for 
the use of MCS devices—that one of these devices inserted rapidly if hemodynamic stability 
cannot be achieved rapidly with pharmacotherapy.
Other devices are being used such as the right ventricular assist devices (RVAD), which is 
used for the failing RV, and others. For further read on these devices and other MCS devices, 
refer to the 2015 SCAI/ACC/HFSA/STS expert consensus statement on the use of percutane-
ous MCS [43].
7. Treatment considerations in non-ACS related CS
The mechanical complications of AMI such as acute MR, papillary muscle rupture, ventricu-
lar septal rupture and LV free wall rupture are catastrophic, and carry very high mortality and 
are surgical emergencies. IABP helps stabilize these patients, especially acute MR patients, 
and the other MCS devices can be used in these situations as well.
RV failure resulting in CS also carries high mortality; ECMO or RVAD might be especially 
helpful in this situation. In CS secondary to massive pulmonary embolism, fibrinolysis (or 
mechanical thrombectomy) might be helpful, and in RV failure secondary to severe pulmo-
nary arterial hypertension, the use of pulmonary hypertension (PH) specific therapy might 
provide improvement in the PA pressures and RV function.
The treatment considerations in acute decompensated heart failure (ADHF) and end stage 
cardiomyopathy are those of the heart failure guidelines [20], and the above-mentioned MCS 
devices can be used interchangeably.
In most patients with myocarditis, the course is usually self-limiting and presents with 
acute heart failure; on the other hand, fulminant myocarditis will present with acute severe 
heart failure and even CS. Close to 90% of patients with fulminant myocarditis will have 
full recovery with minimal long-term sequelae if recognized early. The treatment of CS sec-
ondary to fulminant myocarditis includes hemodynamic support with pharmacotherapy or 
MCS devices, along with high dose steroids with or without immunosuppressants if giant cell 
myocarditis is diagnosed [58].
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8. Summary and conclusion
Cardiogenic shock still carries high morbidity and mortality and remains the leading cause 
of death in acute myocardial infarction patients. Early recognition and treatment is the key 
to improving survival, and early revascularization in CS secondary to myocardial infarction 
remains the cornerstone of therapy in these patients. The early use of vasopressors/inotropes is 
recommended in this population, and the early use of the mechanical circulatory support devices 
is encouraged if hemodynamic stability cannot be achieved rapidly with pharmacotherapy.
One should keep in mind the mechanical complications of myocardial infarction and the 
grave prognosis if not recognized early.
There is a multitude of etiologies for non-ACS related cardiogenic shock; those should be 
treated similarly with vasopressors/inotropes, and MCS devices, keeping in mind guidelines 
directed medical therapy for those with congestive heart failure.
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